79944-44-8

Basic information

• Product Name: 1,3-Benzenedicarbonyl dichloride, 5,5'-[(1,3-dioxo-1,3-propanediyl)diimino]bis[2,4,6-triiodo-
• CAS NO: 79944-44-8
• Molecular Formula: C19H4Cl4I6N2O6
• Molecular Weight: 1259.49
• Mol File: 79944-44-8.mol
• Article Data: 7

Chemical Properties

• CAS DataBase Reference: 1,3-Benzenedicarbonyl dichloride, 5,5'-[(1,3-dioxo-1,3-propanediyl)diimino]bis[2,4,6-triiodo-(CAS DataBase Reference)
• NIST Chemistry Reference: 1,3-Benzenedicarbonyl dichloride, 5,5'-[(1,3-dioxo-1,3-propanediyl)diimino]bis[2,4,6-triiodo-(79944-44-8)
• EPA Substance Registry System: 1,3-Benzenedicarbonyl dichloride, 5,5'-[(1,3-dioxo-1,3-propanediyl)diimino]bis[2,4,6-triiodo-(79944-44-8)

Safety Data

• Hazardous Substances Data: 79944-44-8(Hazardous Substances Data)

Upstream product

• 37441-29-5 5-amino-2,4,6-triiodoisophthalic acid dichloride 
• 1663-67-8 malonoyl dichloride 
• 35453-19-1 2,4,6-triiodo-5-aminoisophthalic acid 
• 99-31-0 5-aminoisophthalic acid 

Downstream Products

• 1187316-83-1 tetra-tert-butyl [({5,5′-[malonylbis(azanediyl)]bis(2,4,6-triiodoisophthaloyl)}tetrakis(azanediyl))tetrakis(ethane-2,1-diyl)]tetracarbamate 
• 915228-77-2 C₇₅H₈₀I₆N₁₀O₂₂ 

Relevant articles and documents

Synthesis and Preclinical Characterization of a Cationic Iodinated Imaging Contrast Agent (CA4+) and Its Use for Quantitative Computed Tomography of Ex Vivo Human Hip Cartilage

Contrast agents that go beyond qualitative visualization and enable quantitative assessments of functional tissue performance represent the next generation of clinically useful imaging tools. An optimized and efficient large-scale synthesis of a cationic iodinated contrast agent (CA4+) is described for imaging articular cartilage. Contrast-enhanced CT (CECT) using CA4+ reveals significantly greater agent uptake of CA4+ in articular cartilage compared to that of similar anionic or nonionic agents, and CA4+ uptake follows Donnan equilibrium theory. The CA4+ CECT attenuation obtained from imaging ex vivo human hip cartilage correlates with the glycosaminoglycan content, equilibrium modulus, and coefficient of friction, which are key indicators of cartilage functional performance and osteoarthritis stage. Finally, preliminary toxicity studies in a rat model show no adverse events, and a pharmacokinetics study documents a peak plasma concentration 30 min after dosing, with the agent no longer present in vivo at 96 h via excretion in the urine.

Synthesis and evaluation of potential CT (computer tomography) contrast agents for bone structure and microdamage analysis

The design and synthesis of several novel X-ray contrast agents 1-3, developed for targeting bone structures, and in particularly microcracks in bones, using CT (Computer Tomography) detection is described. These contrast agents are based on the use of the well known triiodobenzene platform, which was conjugated into one or more phenyliminodiacetate moieties, which can be used to 'lock' onto bone matrices. Compounds 1-3 were all tested for their ability to visualise cracks in bone structures (bovine bones) using μ-CT imaging. The Royal Society of Chemistry 2006.

Toward fullerene-based X-ray contrast agents: Design and synthesis of non-ionic, highly-iodinated derivatives of C60

An X-ray contrast agent precursor based on C60 has been designed, synthesized, and characterized. The compound is the monoadduct of a malonodiamide containing six iodine atoms and eight acetal-protected alcohols with multiple hindered rotations